CA2236998C - Tissue-specific and target rna-specific ribozymes - Google Patents
Tissue-specific and target rna-specific ribozymes Download PDFInfo
- Publication number
- CA2236998C CA2236998C CA002236998A CA2236998A CA2236998C CA 2236998 C CA2236998 C CA 2236998C CA 002236998 A CA002236998 A CA 002236998A CA 2236998 A CA2236998 A CA 2236998A CA 2236998 C CA2236998 C CA 2236998C
- Authority
- CA
- Canada
- Prior art keywords
- ribozyme
- nucleic acid
- sequence
- specific
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000994 Catalytic RNA Proteins 0.000 title claims abstract description 221
- 102000053642 Catalytic RNA Human genes 0.000 title claims abstract description 220
- 108091092562 ribozyme Proteins 0.000 title claims abstract description 220
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 72
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 76
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 74
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 74
- 230000003197 catalytic effect Effects 0.000 claims abstract description 31
- 230000009870 specific binding Effects 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 210000001519 tissue Anatomy 0.000 claims description 65
- 239000013598 vector Substances 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000002307 prostate Anatomy 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 20
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 108010042121 probasin Proteins 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 239000012678 infectious agent Substances 0.000 claims description 9
- 108020004418 ribosomal RNA Proteins 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 abstract description 22
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 208000036142 Viral infection Diseases 0.000 abstract description 11
- 230000009385 viral infection Effects 0.000 abstract description 10
- 230000014509 gene expression Effects 0.000 description 27
- 239000002502 liposome Substances 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 15
- 230000007017 scission Effects 0.000 description 14
- 238000012384 transportation and delivery Methods 0.000 description 14
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 12
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000004570 RNA-binding Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 102000017143 RNA Polymerase I Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000030852 Parasitic disease Diseases 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 108010013845 RNA Polymerase I Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 108010008594 epithelial membrane protein-1 Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000018780 Replication Protein A Human genes 0.000 description 1
- 108010027643 Replication Protein A Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides tissue-specific and target RNA--specific ribozymes. These ribozymes can be used to destroy target-specific neoplasms and to treat viral infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme. The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. Methods of treating disease by administering the ribozymes are provided.
Description
TISSUE-SPECIFIC AND TARGET RNA-SPECIFIC
RIBOZYMES
BACKGROUND OF THE INVENTION
Field of the Invention The invention pertains to the use of tissue-specific and target RNA-specific ribozymes for treatment of cancers and bacterial, parasitic and viral infections. More specifically, the invention relates to a ribozyme targeted to the RNA
polymerase 1(A) under the control of the probasin promoter.
Background Art A ribozyme is a catalytic RNA molecule that cleaves RNA in a sequence specific manner. The use of ribozyme as potential gene regulators in mammalian cells and antiviral agents has been suggested, but subject to serious questions regarding technical feasibility. For example, it is not known how ribozymes can be introduced to target cells or how they can be directed to the same subcellular compartments as their target RNAs.
Other questions concern the effects of target RNA secondary structure on ribozymal activity. The art has not been successful in answering any of these questions.
Furthermore, because ribozymes are a form of antisense technology, the problems encountered in applying antisense technology to disease treatment are also encountered in the use of ribozyme technology. For example, it has been shown that the expression of antisense RNA in transgenic mice did not invariably lead to a reduction in target RNA molecules, and when reduction in target RNA molecules did occur, it was not predictably paralleled by a reduction in protein. Even when protein levels were reduced sometimes no biological effect was detected (Whitton, J. Lindsay "Antisense Treatment of Viral Infection" Adv. in Virus Res. Vol. 44, 1994).
The experience in the art suggests that it is also not clear whether ribozymes work best when free, or when embedded in an unrelated large RNA molecule (Whitton, 1994). At present, sufficient data are not available, either in vitro or in cell culture to allow systematic comparison of the transactivities of free ribozymes with their embedded equivalents. There have been some studies that focus on the potential use of ribozyme technology in the treatment of cancer. In these studies, ribozymes have been directed against both c-fos and c-ras oncogenes in cell culture and showed some suppression of the malignant potential of cells when transplanted into mice. Nevertheless, these ribozymes specifically target an oncogene.
There has been no suggestion in the literature that tissue-specific cancers or other tissue-specific disease can be treated by delivering to that tissue a ribozyme having a tissue-specific promoter, and that it is targeted to an RNA that is essential for cell survival. The invention provides such a ribozyme capable of treating tissue-specific cancers and other tissue-specific diseases.
The magnitude of the prostate cancer problem requires little introduction.
Approximately 44,000 men die each year of prostate cancer and about 10,000,000 men have precancerous conditions of the prostate. It is clear that new approaches to therapy are needed. Animal models for testing therapeutic approaches are just becoming available, and will require a number of years for validation. However, the present invention provides important reagents to address this problem.
One of the difficulties in using gene therapy to treat prostate cancer is the long standing problem of target-specific delivery. However, the recently developed probasin promoter provides target target-specificity enabling systemic delivery of the present ribozyme-encoding vector (Greenburg et al. Mol. Endocrinol. 8:230-239, 1994).
The present vector consists of a tandem array of 3 hammerhead ribozymes, the 5' and 3' of which are designed to autocatalytically cleave themselves from the primary transcript.
This novel construct eliminates problems inherent with extensive residual flanking sequences which might otherwise be present to compromise catalytic activity and specificity. The present constructs couple the prostate specific probasin promoter to triple-ribozymes targeted at mRNAs critical for prostate cell growth.
Endogenous delivery of a ribozyme under the control of a tissue-specific or other promoter can be complicated by "leakiness", where low levels of transcription occur in extraneous tissues. This could present a considerable therapeutic problem, depending upon the cellular target chosen. The present ribozyme compensates for this problem by targeting a cellular target which is associated with high levels of product (that is, RNA
polymerase I produces large amounts of cellular ribosomal RNA). Thus, in the event promoter leakiness occurs in unintended tissues, it is not likely that cell death would occur. This choice, therefore, provides a needed level of safety, and targeting of pol I
would be applicable to many selected tissues using other promoters.
A common problem in gene therapy is the difficulty in delivering the ribozyme to the correct tissue. The present invention avoids this difficulty by targeting the ribozyme to non-cellular RNAs in cells to which ribozyme constructs can be efficiently delivered.
IV liposome delivery will be effective for treatment of HBV hepatitis. IV
and/or extracorporeal treatment will effectively delivery construct to erythrocytes for treatment of malarial infection. And topical (with or without iv) administration will effectively deliver ribozyme construct to cervical epithelium in dysplastic/precancerous/cancerous HPV 16 cervical lesions. This latter example is of extreme importance for treatment of dysplastic/carcinoma in situ lesions diagnosed via abnormal Pap smears. A
second advantageous facet of the non-cellular target ribozymes is that even if promoter leakiness and/or extraneous delivery and/or expression of the ribozyme occurs in unintended cells, the ribozymes should not cleave any cellular RNAs.
SUMMARY OF THE INVENTION
The invention provides tissue-specific and target RNA-specific ribozymes.
These ribozymes can be used to destroy target-specific neoplasms and to treat viral infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target =
RNA-specific binding site and a 3' autocatalytically cleaving ribozyme.
The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. The nucleic acids of the invention comprise a tissue-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
A method of treating a subject having a proliferative disease of a specific tissue by inhibiting cell proliferation in the tissue, comprising administering to the subject the nucleic acid of claim 5, wherein the target-specific promoter binding sequence is specific for the diseased tissue, whereby the ribozyme encoded by the nucleic acid is expressed, ribosomal RNA production in the tissue is inhibited, cell proliferation is inhibited, and the proliferative disease treated is provided.
A method is provided for treating a subject having prostate cancer, comprising administering to the subject the nucleic acid of claim 7, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
A method of treating an infection in a subject, comprising administering to the subject the nucleic acid of claim 1, wherein the encoded target RNA-specific binding site is specific for an RNA unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed is also provided. =
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 shows DNA encoding the parental double ribozyme starting at Not I site.
Underlined sequences are Not I sites (GCGGCCGC) and Bgl II (AGATCT). Sequence 5 of parental double ribozyme starting at Not I site. Underlined sequences are Not I sites (GCGGCCGC) and Bgl II (AGATCT) Fig. 2 shows DNA encoding the entire sequence with the internal Pol I targeted triple ribozyme in bold. Underlined sequences are Not I (GCGGCCGC) and Bgl II
(AGATCT). This is the entire sequence with the internal Pol I targeted triple ribozyxne in bold. Underlined sequences are Not I (GCGGCCGC) and Bgl II (AGATCT) Fig. 3 shows the two dimensional structure of parent double ribozyme into which the core ribozyme was cloned, as its reverse complement DNA.
DETAILED DESCRIPTION OF THE INVENTION
Ribozymes The invention provides tissue-specific and target RNA-specific ribozymes.
These ribozymes can be used to destroy tissue-specific neoplasms and to treat viral, bacterial or parasitic infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme. One example of the present ribozyme is shown in by its DNA
coding sequence in Fig. 2 and in SEQ ID NO: 1. The nucleotides numbered 1-164 encode the ribozyme, including the 5' and 3' autocatalytic ribozyme sequences. The 5' autocatalytically cleaving ribozyme, catalytic ribozyme, and 3' autocatalytically cleaving = ribozyme of this exemplary ribozyme are shown separately in SEQ ID No:1.
,,. ,.
RIBOZYMES
BACKGROUND OF THE INVENTION
Field of the Invention The invention pertains to the use of tissue-specific and target RNA-specific ribozymes for treatment of cancers and bacterial, parasitic and viral infections. More specifically, the invention relates to a ribozyme targeted to the RNA
polymerase 1(A) under the control of the probasin promoter.
Background Art A ribozyme is a catalytic RNA molecule that cleaves RNA in a sequence specific manner. The use of ribozyme as potential gene regulators in mammalian cells and antiviral agents has been suggested, but subject to serious questions regarding technical feasibility. For example, it is not known how ribozymes can be introduced to target cells or how they can be directed to the same subcellular compartments as their target RNAs.
Other questions concern the effects of target RNA secondary structure on ribozymal activity. The art has not been successful in answering any of these questions.
Furthermore, because ribozymes are a form of antisense technology, the problems encountered in applying antisense technology to disease treatment are also encountered in the use of ribozyme technology. For example, it has been shown that the expression of antisense RNA in transgenic mice did not invariably lead to a reduction in target RNA molecules, and when reduction in target RNA molecules did occur, it was not predictably paralleled by a reduction in protein. Even when protein levels were reduced sometimes no biological effect was detected (Whitton, J. Lindsay "Antisense Treatment of Viral Infection" Adv. in Virus Res. Vol. 44, 1994).
The experience in the art suggests that it is also not clear whether ribozymes work best when free, or when embedded in an unrelated large RNA molecule (Whitton, 1994). At present, sufficient data are not available, either in vitro or in cell culture to allow systematic comparison of the transactivities of free ribozymes with their embedded equivalents. There have been some studies that focus on the potential use of ribozyme technology in the treatment of cancer. In these studies, ribozymes have been directed against both c-fos and c-ras oncogenes in cell culture and showed some suppression of the malignant potential of cells when transplanted into mice. Nevertheless, these ribozymes specifically target an oncogene.
There has been no suggestion in the literature that tissue-specific cancers or other tissue-specific disease can be treated by delivering to that tissue a ribozyme having a tissue-specific promoter, and that it is targeted to an RNA that is essential for cell survival. The invention provides such a ribozyme capable of treating tissue-specific cancers and other tissue-specific diseases.
The magnitude of the prostate cancer problem requires little introduction.
Approximately 44,000 men die each year of prostate cancer and about 10,000,000 men have precancerous conditions of the prostate. It is clear that new approaches to therapy are needed. Animal models for testing therapeutic approaches are just becoming available, and will require a number of years for validation. However, the present invention provides important reagents to address this problem.
One of the difficulties in using gene therapy to treat prostate cancer is the long standing problem of target-specific delivery. However, the recently developed probasin promoter provides target target-specificity enabling systemic delivery of the present ribozyme-encoding vector (Greenburg et al. Mol. Endocrinol. 8:230-239, 1994).
The present vector consists of a tandem array of 3 hammerhead ribozymes, the 5' and 3' of which are designed to autocatalytically cleave themselves from the primary transcript.
This novel construct eliminates problems inherent with extensive residual flanking sequences which might otherwise be present to compromise catalytic activity and specificity. The present constructs couple the prostate specific probasin promoter to triple-ribozymes targeted at mRNAs critical for prostate cell growth.
Endogenous delivery of a ribozyme under the control of a tissue-specific or other promoter can be complicated by "leakiness", where low levels of transcription occur in extraneous tissues. This could present a considerable therapeutic problem, depending upon the cellular target chosen. The present ribozyme compensates for this problem by targeting a cellular target which is associated with high levels of product (that is, RNA
polymerase I produces large amounts of cellular ribosomal RNA). Thus, in the event promoter leakiness occurs in unintended tissues, it is not likely that cell death would occur. This choice, therefore, provides a needed level of safety, and targeting of pol I
would be applicable to many selected tissues using other promoters.
A common problem in gene therapy is the difficulty in delivering the ribozyme to the correct tissue. The present invention avoids this difficulty by targeting the ribozyme to non-cellular RNAs in cells to which ribozyme constructs can be efficiently delivered.
IV liposome delivery will be effective for treatment of HBV hepatitis. IV
and/or extracorporeal treatment will effectively delivery construct to erythrocytes for treatment of malarial infection. And topical (with or without iv) administration will effectively deliver ribozyme construct to cervical epithelium in dysplastic/precancerous/cancerous HPV 16 cervical lesions. This latter example is of extreme importance for treatment of dysplastic/carcinoma in situ lesions diagnosed via abnormal Pap smears. A
second advantageous facet of the non-cellular target ribozymes is that even if promoter leakiness and/or extraneous delivery and/or expression of the ribozyme occurs in unintended cells, the ribozymes should not cleave any cellular RNAs.
SUMMARY OF THE INVENTION
The invention provides tissue-specific and target RNA-specific ribozymes.
These ribozymes can be used to destroy target-specific neoplasms and to treat viral infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target =
RNA-specific binding site and a 3' autocatalytically cleaving ribozyme.
The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. The nucleic acids of the invention comprise a tissue-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
A method of treating a subject having a proliferative disease of a specific tissue by inhibiting cell proliferation in the tissue, comprising administering to the subject the nucleic acid of claim 5, wherein the target-specific promoter binding sequence is specific for the diseased tissue, whereby the ribozyme encoded by the nucleic acid is expressed, ribosomal RNA production in the tissue is inhibited, cell proliferation is inhibited, and the proliferative disease treated is provided.
A method is provided for treating a subject having prostate cancer, comprising administering to the subject the nucleic acid of claim 7, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
A method of treating an infection in a subject, comprising administering to the subject the nucleic acid of claim 1, wherein the encoded target RNA-specific binding site is specific for an RNA unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed is also provided. =
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 shows DNA encoding the parental double ribozyme starting at Not I site.
Underlined sequences are Not I sites (GCGGCCGC) and Bgl II (AGATCT). Sequence 5 of parental double ribozyme starting at Not I site. Underlined sequences are Not I sites (GCGGCCGC) and Bgl II (AGATCT) Fig. 2 shows DNA encoding the entire sequence with the internal Pol I targeted triple ribozyme in bold. Underlined sequences are Not I (GCGGCCGC) and Bgl II
(AGATCT). This is the entire sequence with the internal Pol I targeted triple ribozyxne in bold. Underlined sequences are Not I (GCGGCCGC) and Bgl II (AGATCT) Fig. 3 shows the two dimensional structure of parent double ribozyme into which the core ribozyme was cloned, as its reverse complement DNA.
DETAILED DESCRIPTION OF THE INVENTION
Ribozymes The invention provides tissue-specific and target RNA-specific ribozymes.
These ribozymes can be used to destroy tissue-specific neoplasms and to treat viral, bacterial or parasitic infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme. One example of the present ribozyme is shown in by its DNA
coding sequence in Fig. 2 and in SEQ ID NO: 1. The nucleotides numbered 1-164 encode the ribozyme, including the 5' and 3' autocatalytic ribozyme sequences. The 5' autocatalytically cleaving ribozyme, catalytic ribozyme, and 3' autocatalytically cleaving = ribozyme of this exemplary ribozyme are shown separately in SEQ ID No:1.
,,. ,.
Alternatively, the 5' autocatalytically cleaving ribozyme can be replaced with another stretch of transcribed RNA. In this RNA, the first 20-30 nt (or longer) are followed by a sequence which represents the reverse complement of the initial,20-30 nt.
This way, the construct would presumably still be capped at the 5' end the way pol II
transcripts are, but the initial nucleotides should not alter the specificity of the nucleotides on the 5' side of the targeted middle ribozyme. Based upon the fact that the transcript would be capped, it should be exported efficiently to the cytoplasm. For present triple ribozyme construct having both 5' and 3' autocatalytic ribozymes, it is expected that there will be some diffusion mediated transport to the cytoplasm of the internal targeted ribozyme, although this altemative 5' end should increase the cytoplasmic proportion.
The invention provides ribozymes that have the unique characteristic of being both target RNA-specific in their catalytic action, and subject to tissue-specific expression. In the example shown in Fig. I and SEQ ID NO: 1, the target RNA
specificity is conferred by an RNA binding site that specifically binds a sequence that is unique to RNA polymerase I(A) (ribosomal RNA polymerase). It will be understood that an RNA sequence unique fbr any RNA can be the target of the present target RNA-specific ribozyme. The determination of unique sequences is routine given the availability of numerous computer databases (GenBank) and computer programs (Genetics Computer Group, PCGENE and BLAST) which can search for and find any matches between nucleic acid sequences. A unique DNA sequence located on one of the databases will have a corresponding unique RNA sequence.
One example of the catalytic sequence of the present ribozymes is also shown as its DNA coding sequence in Fig. I and SEQ ID NO:1. Other catalytic sequences include those known in the art. A number of sequence variation have defined permissible nucleotide alteration in "stem" regions (Fedor and Uhlenbeck Proc.
Nat.
Acad. Sci. 87:1668-1672, 1990). Those skilled in the art will understand that any catalytic sequence, even those not yet discovered, can be used to construct a ribozyme * trademark of the invention when it is routinely combined with the autocatalytically cleaving ribozymes and RNA binding site as described herein.
= One example of the 5' and 3' autocatalytically cleaving ribozymes that are expressed with the catalytic ribozyme of the invention are shown in Fig. 1 and SEQ ID
NO: 1, and also in Figs. 2 and 3. As further described below, these ribozymes are important for the expression of the catalytic ribozyme, because they cleave off of the ribozyme transcript as soon as they are transcribed to produce a catalytic ribozyme having minimal extraneous 5' or 3' sequences. Thus, the target-specific binding site and the catalytic sequence that comprise the catalytic ribozyme are in the correct configuration to bind and cleave the target RNA. The extraneous sequences in the exemplified construct are the result of the cloning procedure. It is understood that with the selection of an alternative cloning scheme some or all of these extraneous nucleotides can be elinzinated.
Ribozyme Encoding Nucleic Acids The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. The site can be tissue-specific in the case of treating tissue-specific cancers, or it can be target-specific in the case of ribozymes that prevent replication of infectious agents to treat infection (e.g. hepatitis, herpes, malaria, tuberculosis, etc.).
The nucleic acids of the invention comprise a tissue-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
The tissue-specific promoter binding site in the ribozyme-producing construct results in tissue-specific expression of the ribozyme in tissue(s) that actively transcribe RNA from the selected promoter. Thus, only the target RNA in tissue that utilizes the promoter will be cleaved by the ribozyme. The exemplary ribozyme shown in Fig.
I and SEQ ID NO:1 uses the binding site for the probasin promoter, a promoter-specific for prostate epithelium (Greenburg et al., 1994)). This tissue-specific promoter binding site has the sequence shown in (Greenburg et al., 1994).
As expected, other tissue-specific promoters can be used in the present nucleic acid constructs. Examples of these promoters include the binding sites for prostate-specific antigen (prostate), albumin (liver), fatty acid binding protein (ilium), whey acidic protein (breast), smooth muscle action (smooth muscle), etc. It will also be clear that target-specific promoters not yet identified can be used to target expression of the present ribozymes to the selected tissue(s). Once a target-specific promoter is identified its binding sequence can be routinely determined by routine methods such as sequence analysis. The promoter is defined by deletion analysis, mutagenesis, footprinting, gel shifts and transfection analyses (Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).
In the ribozyme-encoding nucleic acid of the invention, the nucleic acid encoding the 5' autocatalytically cleaving ribozyme can have the sequence of nucleotides 1-54 shown in SEQ ID NO:1. In the ribozyme-encoding nucleic acid of the invention, the nucleic acid encoding the 3' autocatalytically cleaving ribozyme can have the sequence of nucleotides 111-164 shown in SEQ ID NO:1.
It is understood that other 5' and 3' autocatalytically cleaving ribozymes may be developed that can be encoded by the present nucleic acids. These ribozymes can be developed according to the methods of Taira et al. (Nuc. Acids Res.
19(19):5125-5130, 1991).
The present nucleic acid encodes a catalytic ribozyme that contains two separable functional regions: a highly conserved catalytic sequence which cleaves the target RNA (also known as the "catalytic core"), and flanking regions which include a target RNA-specific binding site. By nucleic acid complementarity, the binding site directs the ribozyme core to cleave a specific site on the target RNA
molecule. The = length of flanking sequences have implications not only for specificity, but also for the cleavage efficiency of the individual ribozyme molecules. In the present catalytic ribozyme, the flanking sequences are highly specific for the target RNA, yet allow ready dissociation from the target RNA once cleavage occurs. This permits cycling of the ribozyme (with an expected Kcat of about 1 cleavage per minute) and reduces the amount of ribozyme required to be effective. A range of binding/dissociation values from 16-21 Kcal should be effective.
The complexity of human RNA is about 100 fold lower than that for human DNA, and specificity can be achieved with as few as 12-15 base pairs. The stability of the RNA-RNA duplex is effected by several factors, such as GC content, temperature, pH, ionic concentration, and structure. The nearest neighbor rules can provide a useful estimate of the stability of the duplex (Castanotto et al. "Antisense Catalatic RNAs as Therapeutic Agents" Advances in Pharmacol. 25:289-317, 1994).
As described above, the encoded RNA binding site is unique, so the encoding nucleic acid sequence will be the corresponding unique DNA sequence. The RNA
binding site can comprise a sequence that binds to an RNA sequence unique to ribosomal RNA polymerase I(A) subunit. The ribosomal RNA polymerase binding site encoding DNA can have the sequence shown in Fig. 3. This is a sequence from the RNA polymerase I(A) subunit.
The catalytic ribozyme of the invention also includes a catalytic sequence, which cleaves the target RNA near the middle of the site to which the target RNA-specific binding site binds. In the hammerhead type of ribozyme, the catalytic sequence is generally highly conserved. The conserved catalytic core residues are 5' CUGANGA 3' and 5' GAAA 3' linked by an evolutionarily conserved stem-loop structure.
= _ _.
The most conserved and probably most efficiently cleaved sequence on the target RNA is 5' GUC 3'. However, XUN (N = A, U or C) can also be cleaved efficiently.
Such cleavage sites are ubiquitous in most RNAs allowing essentially all RNA's to be targeted (Whitton, J. Lindsay "Antisense Treatment of Viral Infection" Adv. in Virus 5 Res. Vol. 44, 1994).
With regard to the selection of the appropriate sites on target RNA, it is known that target site secondary structure can have an effect on cleavage in vitro (Whitton, 1994). Thus, the selected target molecule's sequence can be routinely screened for 10 potential secondary structure, using the program RNAFOLD*(from the PCGENE
group of programs or available on the Internet). Thus, reasonable predictions of target accessibility can be made. Computer assisted RNA folding (Castanotto et al., 1994), along with computational analysis for 3-dimensional modeling of RNA (Major et al., Science 253:1255-1260, 1991 and Castanotto et al., 1994) is certainly effective in guiding the choice of cleavage sites.
The internal ribozyme can be targeted to noncellular RNAs necessary for growth of parasites, virus life cycles, etc., and expression can be driven with tissue-specific or virus-specific promoters. Three important examples which are specifically presented in the applicaxion are:
A) Use of the albumin promoter with a Hepatitis B virus target (chosen to cleave the viral RNA pregenome, S protein, and polymerase/reverse transcriptase transcripts using the same ribozyme target site);
B) Use of generic promoters active in erythrocytes, using a ribozyme targeted to highly conserved regions of the EMP-1 protein family from P. faiciparum, which are necessary for cytoadherence and antigenic variation in malaria; and C) Use of the HPV promoter, with a ribozyme targeted to a specific site near the translational start site of the E6 protein, a site known to be critical for expression of both the E6 and E7 proteins which are intimately involved in cervical carcinogenesis.
* trademark One example of the nucleic acid of the invention has the nucleotides in the sequence shown in the Sequence Listing as SEQ ID NO: 1. This exemplary nucleic acid includes a probasin promoter, upstream from a sequence that encodes the 5' autocatalytically cleaving ribozyme having the sequence shown in SEQ ID NO: 1, the ribosomal RNA binding site encoding DNA having the sequence shown in the Sequence Listing as SEQ ID NO:1 and the 3' autocatalytically cleaving ribozyme having the sequence shown in SEQ ID NO: 1.
Alternatively, silent base substitutions in the promoter binding site and ribozyme encoding sequence can be made that express the same ribozyme in the same tissue.
Thus, a nucleic acid having substantially the nucleotide sequence shown in SEQ
ID
NO: 1, which encodes the ribozyme shown in SEQ ID NO: 1, is provided. The nucleic acid can vary based on the characteristics/definition of the promoter chosen, and will have 80%-99% sequence identity with SEQ ID NO: 1, more preferably, it will have 90%-99% sequence identity with SEQ ID NO: 1. Other modifications could include for example, changes (or deletion) of nucleotides inserted for cloning purposes (Fig. 2), which include -1 to -8, +69 to +76. In Figure 3, the box includes extraneous nucleotides that are a function of cloning choices and, thus, can be modified. The unpaired bases can be any base, determined only by the cloning scheme chosen. If one of the bases of a pair is changed, the other must be changed in a complementary fashion.
Furthermore, the ribozyme-coding sequence can be altered in ways that modify the ribozyme sequence, but do not effect the ribozyme's target RNA-specificity or negate its cleavage activity. For example, changes in the stem loop regions of the 5', 3', and internal ribozyme (Fig. 2) could be incorporated into other constructs while maintaining catalytic activity (Fedor and Uhlenbeck, 1990).
Synthesis of the Ribozyme Producing Construct Typically, the RNA binding and core sequences are synthesized as reverse complementary oligonucleotides and are cloned into a vector that will allow production of the relevant RNA containing the ribozyme. The present ribozymes are prepared by synthesis of an oligonucleotide (5' GGA AGA TCT TTC AAA GAC TGA TGA CTC
CGT GAG GAC GAA ACG AGG ATC AGA TCT TCC 3') and its reverse complement. The Bgl II site used in cloning is underlined. Following appropriate restriction digestion, in this particular case Bgl II, the double-stranded DNA
oligonucleotide is cloned into the multiple cloning site within the parent vector (Figure 1).
Functional Testing Once sequenced, these ribozymes are functionally tested. The test can involve transcription of the ribozyme using one of the two possible bacterial promoters, in this case SP-6 or T-7, (in the presence of trace amounts of radioactivity) followed by evaluating the autocatalytic cleavage of the ribozyme by electrophoresis. Data from these tests are provided in the Examples.
Additional testing procedures encompass incubation of in vitro transcribed ribozymes with in vitro synthesized target RNA transcript or with cytoplasmic RNA
preparations. Following incubations, RNAs are examined by standard Northern blot analyses to verify specific degradation of target RNA transcripts.
The triple-ribozyme that has been constructed can be further tested by subcloning it behind one of the tissue-specific promoters that will drive expression of the vector in a tissue-specific manner in the target. Data from these tests are provided in the Examples.
Finally, the triple-ribozyme experimental approach is further validated by doing in vivo studies in nzice. Two such studies have been performed as described in the Examples. The first case used a control vector more easily monitored than the pol I
ribozyme consisting of the probasin promoter driving expression of algal green fluorescent protein (pBGFT). This test vector is used to ascertain the effectiveness of our in vivo delivery system. A second experiment has also been carried out in which the pol I ribozyme is introduced. In both cases where either the triple ribozyme or the green fluorescent protein was introduced, the animals were euthanized at various time post operatively, autopsied, and various tissue were examined for activity of the vector by immunohistochemistry.
Delivery The nucleic acids of the invention can be in a vector for delivering the nucleic acid to the site for expression of the ribozyme. The vector can be one of the commercially available preparations, such as the pGM plasmid (Promega) Vector delivery can be by liposome, using commercially available liposome preparations or newly developed liposomes having the features of the present liposomes. Other delivery methods can be adopted routinely tested in methods taught herein. An example of a delivery method using liposomes is further described in the Examples.
The modes of administration of the liposome will vary predictably according to the disease being treated and the tissue being targeted. For lung (e.g., tuberculosis, cancer) and liver (e.g., hepatitis and cancer) which are both sinks for liposomes, intravenous administration is reasonable. For many other localized pathologic conditions including cancers, infections (e.g., hepatitis, cystitis, proctitis, cervicitis, etc.) as well as precancerous conditions, catheterization of an artery upstream from the organ is a preferred mode of delivery, because it avoids significant clearance of the liposome by the lung and liver. For lesions at a number of other sites (e.g., skin cancer, human papilloma virus infection, herpes (oral or genital) and precancerous cervical dysplasia), topical delivery is expected to be effective and may be preferred, because of its convenience.
Leukemias and other conditions such as malaria, may also be more readily treated by ex vivo administration of the ribozyme.
.. , _.
This way, the construct would presumably still be capped at the 5' end the way pol II
transcripts are, but the initial nucleotides should not alter the specificity of the nucleotides on the 5' side of the targeted middle ribozyme. Based upon the fact that the transcript would be capped, it should be exported efficiently to the cytoplasm. For present triple ribozyme construct having both 5' and 3' autocatalytic ribozymes, it is expected that there will be some diffusion mediated transport to the cytoplasm of the internal targeted ribozyme, although this altemative 5' end should increase the cytoplasmic proportion.
The invention provides ribozymes that have the unique characteristic of being both target RNA-specific in their catalytic action, and subject to tissue-specific expression. In the example shown in Fig. I and SEQ ID NO: 1, the target RNA
specificity is conferred by an RNA binding site that specifically binds a sequence that is unique to RNA polymerase I(A) (ribosomal RNA polymerase). It will be understood that an RNA sequence unique fbr any RNA can be the target of the present target RNA-specific ribozyme. The determination of unique sequences is routine given the availability of numerous computer databases (GenBank) and computer programs (Genetics Computer Group, PCGENE and BLAST) which can search for and find any matches between nucleic acid sequences. A unique DNA sequence located on one of the databases will have a corresponding unique RNA sequence.
One example of the catalytic sequence of the present ribozymes is also shown as its DNA coding sequence in Fig. I and SEQ ID NO:1. Other catalytic sequences include those known in the art. A number of sequence variation have defined permissible nucleotide alteration in "stem" regions (Fedor and Uhlenbeck Proc.
Nat.
Acad. Sci. 87:1668-1672, 1990). Those skilled in the art will understand that any catalytic sequence, even those not yet discovered, can be used to construct a ribozyme * trademark of the invention when it is routinely combined with the autocatalytically cleaving ribozymes and RNA binding site as described herein.
= One example of the 5' and 3' autocatalytically cleaving ribozymes that are expressed with the catalytic ribozyme of the invention are shown in Fig. 1 and SEQ ID
NO: 1, and also in Figs. 2 and 3. As further described below, these ribozymes are important for the expression of the catalytic ribozyme, because they cleave off of the ribozyme transcript as soon as they are transcribed to produce a catalytic ribozyme having minimal extraneous 5' or 3' sequences. Thus, the target-specific binding site and the catalytic sequence that comprise the catalytic ribozyme are in the correct configuration to bind and cleave the target RNA. The extraneous sequences in the exemplified construct are the result of the cloning procedure. It is understood that with the selection of an alternative cloning scheme some or all of these extraneous nucleotides can be elinzinated.
Ribozyme Encoding Nucleic Acids The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. The site can be tissue-specific in the case of treating tissue-specific cancers, or it can be target-specific in the case of ribozymes that prevent replication of infectious agents to treat infection (e.g. hepatitis, herpes, malaria, tuberculosis, etc.).
The nucleic acids of the invention comprise a tissue-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
The tissue-specific promoter binding site in the ribozyme-producing construct results in tissue-specific expression of the ribozyme in tissue(s) that actively transcribe RNA from the selected promoter. Thus, only the target RNA in tissue that utilizes the promoter will be cleaved by the ribozyme. The exemplary ribozyme shown in Fig.
I and SEQ ID NO:1 uses the binding site for the probasin promoter, a promoter-specific for prostate epithelium (Greenburg et al., 1994)). This tissue-specific promoter binding site has the sequence shown in (Greenburg et al., 1994).
As expected, other tissue-specific promoters can be used in the present nucleic acid constructs. Examples of these promoters include the binding sites for prostate-specific antigen (prostate), albumin (liver), fatty acid binding protein (ilium), whey acidic protein (breast), smooth muscle action (smooth muscle), etc. It will also be clear that target-specific promoters not yet identified can be used to target expression of the present ribozymes to the selected tissue(s). Once a target-specific promoter is identified its binding sequence can be routinely determined by routine methods such as sequence analysis. The promoter is defined by deletion analysis, mutagenesis, footprinting, gel shifts and transfection analyses (Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).
In the ribozyme-encoding nucleic acid of the invention, the nucleic acid encoding the 5' autocatalytically cleaving ribozyme can have the sequence of nucleotides 1-54 shown in SEQ ID NO:1. In the ribozyme-encoding nucleic acid of the invention, the nucleic acid encoding the 3' autocatalytically cleaving ribozyme can have the sequence of nucleotides 111-164 shown in SEQ ID NO:1.
It is understood that other 5' and 3' autocatalytically cleaving ribozymes may be developed that can be encoded by the present nucleic acids. These ribozymes can be developed according to the methods of Taira et al. (Nuc. Acids Res.
19(19):5125-5130, 1991).
The present nucleic acid encodes a catalytic ribozyme that contains two separable functional regions: a highly conserved catalytic sequence which cleaves the target RNA (also known as the "catalytic core"), and flanking regions which include a target RNA-specific binding site. By nucleic acid complementarity, the binding site directs the ribozyme core to cleave a specific site on the target RNA
molecule. The = length of flanking sequences have implications not only for specificity, but also for the cleavage efficiency of the individual ribozyme molecules. In the present catalytic ribozyme, the flanking sequences are highly specific for the target RNA, yet allow ready dissociation from the target RNA once cleavage occurs. This permits cycling of the ribozyme (with an expected Kcat of about 1 cleavage per minute) and reduces the amount of ribozyme required to be effective. A range of binding/dissociation values from 16-21 Kcal should be effective.
The complexity of human RNA is about 100 fold lower than that for human DNA, and specificity can be achieved with as few as 12-15 base pairs. The stability of the RNA-RNA duplex is effected by several factors, such as GC content, temperature, pH, ionic concentration, and structure. The nearest neighbor rules can provide a useful estimate of the stability of the duplex (Castanotto et al. "Antisense Catalatic RNAs as Therapeutic Agents" Advances in Pharmacol. 25:289-317, 1994).
As described above, the encoded RNA binding site is unique, so the encoding nucleic acid sequence will be the corresponding unique DNA sequence. The RNA
binding site can comprise a sequence that binds to an RNA sequence unique to ribosomal RNA polymerase I(A) subunit. The ribosomal RNA polymerase binding site encoding DNA can have the sequence shown in Fig. 3. This is a sequence from the RNA polymerase I(A) subunit.
The catalytic ribozyme of the invention also includes a catalytic sequence, which cleaves the target RNA near the middle of the site to which the target RNA-specific binding site binds. In the hammerhead type of ribozyme, the catalytic sequence is generally highly conserved. The conserved catalytic core residues are 5' CUGANGA 3' and 5' GAAA 3' linked by an evolutionarily conserved stem-loop structure.
= _ _.
The most conserved and probably most efficiently cleaved sequence on the target RNA is 5' GUC 3'. However, XUN (N = A, U or C) can also be cleaved efficiently.
Such cleavage sites are ubiquitous in most RNAs allowing essentially all RNA's to be targeted (Whitton, J. Lindsay "Antisense Treatment of Viral Infection" Adv. in Virus 5 Res. Vol. 44, 1994).
With regard to the selection of the appropriate sites on target RNA, it is known that target site secondary structure can have an effect on cleavage in vitro (Whitton, 1994). Thus, the selected target molecule's sequence can be routinely screened for 10 potential secondary structure, using the program RNAFOLD*(from the PCGENE
group of programs or available on the Internet). Thus, reasonable predictions of target accessibility can be made. Computer assisted RNA folding (Castanotto et al., 1994), along with computational analysis for 3-dimensional modeling of RNA (Major et al., Science 253:1255-1260, 1991 and Castanotto et al., 1994) is certainly effective in guiding the choice of cleavage sites.
The internal ribozyme can be targeted to noncellular RNAs necessary for growth of parasites, virus life cycles, etc., and expression can be driven with tissue-specific or virus-specific promoters. Three important examples which are specifically presented in the applicaxion are:
A) Use of the albumin promoter with a Hepatitis B virus target (chosen to cleave the viral RNA pregenome, S protein, and polymerase/reverse transcriptase transcripts using the same ribozyme target site);
B) Use of generic promoters active in erythrocytes, using a ribozyme targeted to highly conserved regions of the EMP-1 protein family from P. faiciparum, which are necessary for cytoadherence and antigenic variation in malaria; and C) Use of the HPV promoter, with a ribozyme targeted to a specific site near the translational start site of the E6 protein, a site known to be critical for expression of both the E6 and E7 proteins which are intimately involved in cervical carcinogenesis.
* trademark One example of the nucleic acid of the invention has the nucleotides in the sequence shown in the Sequence Listing as SEQ ID NO: 1. This exemplary nucleic acid includes a probasin promoter, upstream from a sequence that encodes the 5' autocatalytically cleaving ribozyme having the sequence shown in SEQ ID NO: 1, the ribosomal RNA binding site encoding DNA having the sequence shown in the Sequence Listing as SEQ ID NO:1 and the 3' autocatalytically cleaving ribozyme having the sequence shown in SEQ ID NO: 1.
Alternatively, silent base substitutions in the promoter binding site and ribozyme encoding sequence can be made that express the same ribozyme in the same tissue.
Thus, a nucleic acid having substantially the nucleotide sequence shown in SEQ
ID
NO: 1, which encodes the ribozyme shown in SEQ ID NO: 1, is provided. The nucleic acid can vary based on the characteristics/definition of the promoter chosen, and will have 80%-99% sequence identity with SEQ ID NO: 1, more preferably, it will have 90%-99% sequence identity with SEQ ID NO: 1. Other modifications could include for example, changes (or deletion) of nucleotides inserted for cloning purposes (Fig. 2), which include -1 to -8, +69 to +76. In Figure 3, the box includes extraneous nucleotides that are a function of cloning choices and, thus, can be modified. The unpaired bases can be any base, determined only by the cloning scheme chosen. If one of the bases of a pair is changed, the other must be changed in a complementary fashion.
Furthermore, the ribozyme-coding sequence can be altered in ways that modify the ribozyme sequence, but do not effect the ribozyme's target RNA-specificity or negate its cleavage activity. For example, changes in the stem loop regions of the 5', 3', and internal ribozyme (Fig. 2) could be incorporated into other constructs while maintaining catalytic activity (Fedor and Uhlenbeck, 1990).
Synthesis of the Ribozyme Producing Construct Typically, the RNA binding and core sequences are synthesized as reverse complementary oligonucleotides and are cloned into a vector that will allow production of the relevant RNA containing the ribozyme. The present ribozymes are prepared by synthesis of an oligonucleotide (5' GGA AGA TCT TTC AAA GAC TGA TGA CTC
CGT GAG GAC GAA ACG AGG ATC AGA TCT TCC 3') and its reverse complement. The Bgl II site used in cloning is underlined. Following appropriate restriction digestion, in this particular case Bgl II, the double-stranded DNA
oligonucleotide is cloned into the multiple cloning site within the parent vector (Figure 1).
Functional Testing Once sequenced, these ribozymes are functionally tested. The test can involve transcription of the ribozyme using one of the two possible bacterial promoters, in this case SP-6 or T-7, (in the presence of trace amounts of radioactivity) followed by evaluating the autocatalytic cleavage of the ribozyme by electrophoresis. Data from these tests are provided in the Examples.
Additional testing procedures encompass incubation of in vitro transcribed ribozymes with in vitro synthesized target RNA transcript or with cytoplasmic RNA
preparations. Following incubations, RNAs are examined by standard Northern blot analyses to verify specific degradation of target RNA transcripts.
The triple-ribozyme that has been constructed can be further tested by subcloning it behind one of the tissue-specific promoters that will drive expression of the vector in a tissue-specific manner in the target. Data from these tests are provided in the Examples.
Finally, the triple-ribozyme experimental approach is further validated by doing in vivo studies in nzice. Two such studies have been performed as described in the Examples. The first case used a control vector more easily monitored than the pol I
ribozyme consisting of the probasin promoter driving expression of algal green fluorescent protein (pBGFT). This test vector is used to ascertain the effectiveness of our in vivo delivery system. A second experiment has also been carried out in which the pol I ribozyme is introduced. In both cases where either the triple ribozyme or the green fluorescent protein was introduced, the animals were euthanized at various time post operatively, autopsied, and various tissue were examined for activity of the vector by immunohistochemistry.
Delivery The nucleic acids of the invention can be in a vector for delivering the nucleic acid to the site for expression of the ribozyme. The vector can be one of the commercially available preparations, such as the pGM plasmid (Promega) Vector delivery can be by liposome, using commercially available liposome preparations or newly developed liposomes having the features of the present liposomes. Other delivery methods can be adopted routinely tested in methods taught herein. An example of a delivery method using liposomes is further described in the Examples.
The modes of administration of the liposome will vary predictably according to the disease being treated and the tissue being targeted. For lung (e.g., tuberculosis, cancer) and liver (e.g., hepatitis and cancer) which are both sinks for liposomes, intravenous administration is reasonable. For many other localized pathologic conditions including cancers, infections (e.g., hepatitis, cystitis, proctitis, cervicitis, etc.) as well as precancerous conditions, catheterization of an artery upstream from the organ is a preferred mode of delivery, because it avoids significant clearance of the liposome by the lung and liver. For lesions at a number of other sites (e.g., skin cancer, human papilloma virus infection, herpes (oral or genital) and precancerous cervical dysplasia), topical delivery is expected to be effective and may be preferred, because of its convenience.
Leukemias and other conditions such as malaria, may also be more readily treated by ex vivo administration of the ribozyme.
.. , _.
The liposomes may be administered topically, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, excorporeally or the like, although IV or topical administration is typically preferred. The exact amount of the liposomes required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact amount. However, an appropriate amount may be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. Generally, dosage will approximate that which is typical given in the Examples.
Parenteral administration, if used, is generally characterized by injection.
Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795.' Topical administration can be by creams, gels, suppositories and the like. Ex vivo (excorporeal) delivery can be as typically used in other contexts.
Transgenic Animals The invention provides a transgenic non-human animal, containing, in a germ or somatic cell, a nucleic acid comprising a target-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a cataTytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence, wherein the animal expresses a ribozyme comprising a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyrne comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
WO 97/17433 PCTlUS96/18088 The nucleic acid can be the nucleic acid shown in Fig.1 and SEQ ID NO: 1.
Alternatively, silent base substitutions in the promoter binding site and ribozyme encoding sequence can be made that express the same ribozyme in the same tissue. For example, these substitutions can be as described above.
The transgenic non-human animal of the invention is useful, because the animal does not express a phenotype associated with the target RNA (e.g., with the protein it encodes). As used herein the term "phenotype" includes morphology, biochemical profiles (e.g., changes in amounts of RNA or protein expressed, etc.) and other 10 parameters that are affected by the knockout. For example, cell death of otherwise healthy cells can be a measure of altered phenotype resulting from ribozyme expression.
Transformed Host Cells The present ribozymes can be expressed in a transformed cell line. The 15 transformed cell can be used to validate both the specificity of the ribozyme's expression and the specificity and cleavage activity against the target RNA. An example of such a screening function is described in the Examples.
Screening Methods The transgenic animals and transformed host cells of the invention can be used in a method of screening a compound for its ability to cause the animal or host cell to express a phenotype associated with the target RNA. The method requires administering the compound to the animal/cell and assessing the compounds ability to cause expression of the phenotype. If the phenotype is restored, the compound is considered to be effective. For example an L-dopa functional knockout transgenic animal can be made and used to screen for drugs that restore an L-dopa associated phenotype.
Parenteral administration, if used, is generally characterized by injection.
Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795.' Topical administration can be by creams, gels, suppositories and the like. Ex vivo (excorporeal) delivery can be as typically used in other contexts.
Transgenic Animals The invention provides a transgenic non-human animal, containing, in a germ or somatic cell, a nucleic acid comprising a target-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a cataTytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence, wherein the animal expresses a ribozyme comprising a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyrne comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
WO 97/17433 PCTlUS96/18088 The nucleic acid can be the nucleic acid shown in Fig.1 and SEQ ID NO: 1.
Alternatively, silent base substitutions in the promoter binding site and ribozyme encoding sequence can be made that express the same ribozyme in the same tissue. For example, these substitutions can be as described above.
The transgenic non-human animal of the invention is useful, because the animal does not express a phenotype associated with the target RNA (e.g., with the protein it encodes). As used herein the term "phenotype" includes morphology, biochemical profiles (e.g., changes in amounts of RNA or protein expressed, etc.) and other 10 parameters that are affected by the knockout. For example, cell death of otherwise healthy cells can be a measure of altered phenotype resulting from ribozyme expression.
Transformed Host Cells The present ribozymes can be expressed in a transformed cell line. The 15 transformed cell can be used to validate both the specificity of the ribozyme's expression and the specificity and cleavage activity against the target RNA. An example of such a screening function is described in the Examples.
Screening Methods The transgenic animals and transformed host cells of the invention can be used in a method of screening a compound for its ability to cause the animal or host cell to express a phenotype associated with the target RNA. The method requires administering the compound to the animal/cell and assessing the compounds ability to cause expression of the phenotype. If the phenotype is restored, the compound is considered to be effective. For example an L-dopa functional knockout transgenic animal can be made and used to screen for drugs that restore an L-dopa associated phenotype.
Treating Proliferative Diseases A method of treating a subject having a proliferative disease of a specific tissue is provided. The treatment is carried out by inhibiting cell proliferation in the specific tissue, and this is accomplished by administering to the subject a nucleic acid encoding a ribozyme that is targeted to an RNA that is essential to cell survival or replication, and containing a target-specific promoter binding sequence that is specific for the diseased tissue. The ribozyme encoded by the nucleic acid is expressed in the diseased tissue, production of an essential RNA in the tissue is inhibited, cell proliferation is inhibited in the tissue, cell death ensues and the proliferative disease treated.
The proliferative diseases that can be treated by the present method include almost all cancers for which a target-specific promoter exists, including, prostate, breast, colon, pancreatic, lung and liver.
For example, the invention provides a method of treating a subject having prostate cancer, comprising administering to the subject the nucleic acid shown in SEQ
ID NO: 1, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
Treating Viral Infection A method of treating a viral infection in a subject, comprising administering to the subject a nucleic acid of the invention, wherein the encoded target RNA-specific binding site is specific for an RNA unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed.
Transcription can be driven using a virus specific promoter or a tissue-specific promoter which will selectively express the targeted ribozyme in virus-infected tissue, i.e., using the liver- specific albumin promoter for expression of a targeted ribozyme directed against hepatitis B virus.
The proliferative diseases that can be treated by the present method include almost all cancers for which a target-specific promoter exists, including, prostate, breast, colon, pancreatic, lung and liver.
For example, the invention provides a method of treating a subject having prostate cancer, comprising administering to the subject the nucleic acid shown in SEQ
ID NO: 1, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
Treating Viral Infection A method of treating a viral infection in a subject, comprising administering to the subject a nucleic acid of the invention, wherein the encoded target RNA-specific binding site is specific for an RNA unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed.
Transcription can be driven using a virus specific promoter or a tissue-specific promoter which will selectively express the targeted ribozyme in virus-infected tissue, i.e., using the liver- specific albumin promoter for expression of a targeted ribozyme directed against hepatitis B virus.
In the context of determining anti-viral efficacy, ribozyme expressing cell lines can be compared with their ribozyme negative counterparts for their ability to support viral infection/replication/yield. In a manner similar to that described above, ribozyme expressing cell lines can be obtained and assayed; and in all cases the abilities of the ribozyme to prevent infection can be determined.
The present invention will be illustrated in further detail in the following non-limiting examples.
EXAMPLES
ANALYSIS OF RIBOZYME GENE T'HERAPY IN PROSTATE CANCER
This example presents the vectors and a novel strategy to utilizing prostate targeted expression of a hammerhead ribozyme to kill normal and neoplastic prostate epithelium. The ribozyme is a highly innovative, triple-ribozyme targeted to destroy cells by attacking essential RNA(s). The 5' and 3' ribozymes have been designed to undergo autocatalytic cleavage during transcription, freeing the internal ribozyme (at high levels) within the cells.
Intracellular expression of a hammerhead ribozyme, targeted towards an essential cellular RNA (such as RNA polymerase 1(A)), results in the death of the cell.
If the ribozyme is targeted to a specific tissue in a constrained manner, then only cells in that tissue will be affected by expression of the ribozyme. Targeting selectively to prostate can be achieved via the rat probasin promoter (pb) (or the prostate specific antigen promoter). Because tissue-specific prostate targeting exists using the probasin promotor, delivery of vectors systemically or by direct introduction into the prostate will result in death of transfected prostate cancer cells with some collateral damage also being observed in the remaining normal prostate epithelium. Because of the rather unique specificity of the probasin promoter, no additional collateral damage is expected to be observed elsewhere in the body. This is also expected to be true for the prostate-specific antigen.
Examples of targets include the I(A) subunit of RNA polymerase I and II. Other internal targeted ribozymes are tested for in vitro and in vivo activity by the methods described.
Synthesis The primary double ribozyme vector depicted in Figure 1 was constructed. The two flanking ribozymes (bases 1 to 54 and 66 to 120) are capable of self-cleavage. A
third ribozyme (Figure 2)(bases 64 to 105) targeted to pol I mRNA is cloned between the flanking ribozymes. This internal ribozyme has 19 bases within two regions (TTCAAAGA-catalytic core-ACGAGGATCAG) that are anti-sense to the pol I
message and interact by base pairing in regions with minimal secondary structures to effect cleavage.
The internal pol I ribozyme was prepared by synthesis of an oligonucleotide (5' GGA AGA TCT TTC AAA GAC TGA TGA CTC CGT GAG GAC GAA ACG AGG
ATC AGA TCT TCC 3')(only the ribozyme sense strand is shown in its reverse complement). The Bgl II site used in cloning is underlined. Following appropriate restriction digestion with Bgl II the double-stranded oligonucleotide was cloned into the Bgl II site within the parent vector (Figure 1).
Delivery The prostate specific promoter, when coupled to the triple ribozyme construct, will be delivered to the prostate systemically via liposomes. Various routes of introduction into the blood vascular system (some bypassing the lung and liver) are evaluated as described. Orthotopic routes can also be utilized. The liposome vehicle is expected to be efficient enough to deliver the molecule to prostate cancer cells, because of a high degree of vascularization). Thus, curing or at least reducing tumor burden by this gene therapy approach is reasonably expected.
i 1 The following liposome proparations were used in these studies: (a) lipofectamine reagent (GIBCO BRL, Gaithersburg,lvID) is a polycationic lipid composed of a positively charged lipid, DOSPA, and the neutral lipid, DOPE, in a 3:1 molar ration; (b) the cationic lipid, DDAB, used in combination with DOPE at 2:1 or 0.6:1.0 ratios (Brunette et al. Mol. Cell. Biol. 14:2411-2418, 1994); and (c) DIVIRIE in combination with DOPE in a 1:1 molar ratio (Felgner et al. Methods (Orlando) 5:67-75, 1995), obtained from VICAL Corp. (San Diego, CA). Liposome reagents were stored at 4 C prior to transfection.
Testing Once sequenced, these ribozymes are functionally tested: The test mechanism involves transcription of the triple ribozyme using one of the two possible bacterial promoters, in this case SP-6 or T-7 present in the pCRII vector (Invitrogen, San Diego, Ca), (in the presence of trace amounts of radioactivity) followed by evaluating the . autocatalytic cleavage of the ribozyme by electrophoresis. This was carried out with the pol I ribozyme and cleavage was observed, i.e., first a 113 bp fragment was produced that included the iirternal targeting ribozyme and the 3' ribozyme, followed by the appearance of a 74 bp fragment containing the internal pol I ribozyme.
The ribozyme was subsequently tested by transient transfection it into C3H10T
1/2 mouse fibroblast cells. This demonstrated that pol I RNA was degraded when triple ribozyme expression was induced. Thus, two phases of the activity of the molecule have been examined and demonstrated to occur. Autocatalytic cleavage of the cis ribozymes and functional degradation of pol I mRNA in trans occur as expected.
A subsequent step is to introduce the triple-ribozyme into a vector under the control of a tissue-specific promoter such as probasin or prostate specific antigen that will target expression in a tissue-specific manner. This was done by taking the Not I
fragment containing the entire 3', 5' and intenlal ribozymes (Fig. 2) and subcloning it into a vector containing the probasin promoter region (-426 to +28 (Greenburg et al., * trademark 1994)). This promoter has been demonstrated to target gene expression to the prostate.
Vectors are tested in vivo in transgenic mice expressing the triple ribozyme anti-pol I construct. Transgenic mice are generated by standard pronuclear injection as 5 described in Hogan (Manipulating the mouse embryo: a laboratory manual, Cold Spring Harbor, NY 1986). Prior to injection, constructs are separated from vector DNA
by restriction digestion (H'ind III and Sac II) of the plasmid, followed by sucrose gradient fractionation. Isolated constructs are dialyzed against 10mm tris ph 8.0, 0.1mm EDTA
before injection. In these mice, once probasin expression becomes apparent at the 3-5 10 week stage of post natal development destruction of prostate epithelium is expected to occur. The efficiency of generating transgenic mice is 10-15% with twenty-six mice delivered, i.e. 2-3 transgenic mice are predicted. Another way to verify the present ribozymes' functionality is to introduce the vector into tissue culture, e.g., human PC3 prostate cancer cells, and observe cell death in response to activation of the ribozyme.
15 C3H10T 1/2 mouse fibroblasts have been confirmed as sensitive to the pol I
triple ribozyme.
Further validation of this gene therapy approach is obtained through in vivo studies. Two such studies have been performed. In the first case, a control vector, 20 more easily monitored than the pol I ribozyme, which consists of the probasin promoter driving expression of the algal green fluorescent protein was used to ascertain the effectiveness of the in vivo liposomal delivery system. The procedure involves mice that are anesthetized and prepared by a surgical procedure to expose the descending aorta. A 30 gauge catheter is placed in the descending aorta followed by introduction of 300,ug vector/kilogram body weight (vector: liposome ratio of 10gg/40,u1). The results verify that expression of the green fluorescent protein occurs in dorsolateral prostate epithelium but not in the lung (a normal target of liposomes). Further studies determine if expression is observed in liver and other tissue including the kidney, adrenal gland and the brain. A second experiment has also been carried out in which the po1 I
ribozyme was introduced in vivo using the same method described above. In both cases where either the triple ribozyme or the green fluorescent protein was introduced, animals were euthanized at various time post operatively, autopsied, and tissues were examined for activity of the vector by immunohistochemistry. There was evidence of some apoptotic cell death in prostate epithelium at seven days following administration.
In vivo studies are conducted in transgenic mice bearing prostate tumors.
Tumors are induced by probasin directed expression of genes such as EcoRl (a restriction enzyme), cfos (a proto-oncogene), or a modified version of lamin (a nuclear matrix molecule). Administration of the ribozyme is as described above.
Target Choice Various molecules have been chosen for targeting. The first is RNA polymerase 1(A). This represents an excellent target, because it is an abundant RNA. If there is a leakiness (low levels of transcription) of the probasin promoter in other than prostate cells, they are predicted to survive the presence of limited levels of the Pol I ribozyme.
Other potential targets will be examined including phosphofructokinase (ribozyme targets nt 178, 121, or 162 depending on tissue involved), RNA pol II subunit 14.4 kd (ribozyme targets nt 83 or 884), mRNA pol II 140 kd subunit (ribozyme targets nt 204), and RNA pol 1123 kd subunit (ribozyme targets nt 143).
Another potential target of interest is the 70 kD subunit of replication protein A.
It is needed for formation of DNA replication centers/foci, so it should disrupt DNA
replication without danger of introducing errors. The sequence reference is Kim, et al., Mol. Cell. Biol. 12:3050-3059, 1992.
RI[BOZYME GENE THERAPY IN PARASITIC INFECTION
The methods described above are applicable to the present context, except where specified. For example, The administration mode will be different for parasitic infection than for prostate cancer and will depend upon tissue site.
The present invention will be illustrated in further detail in the following non-limiting examples.
EXAMPLES
ANALYSIS OF RIBOZYME GENE T'HERAPY IN PROSTATE CANCER
This example presents the vectors and a novel strategy to utilizing prostate targeted expression of a hammerhead ribozyme to kill normal and neoplastic prostate epithelium. The ribozyme is a highly innovative, triple-ribozyme targeted to destroy cells by attacking essential RNA(s). The 5' and 3' ribozymes have been designed to undergo autocatalytic cleavage during transcription, freeing the internal ribozyme (at high levels) within the cells.
Intracellular expression of a hammerhead ribozyme, targeted towards an essential cellular RNA (such as RNA polymerase 1(A)), results in the death of the cell.
If the ribozyme is targeted to a specific tissue in a constrained manner, then only cells in that tissue will be affected by expression of the ribozyme. Targeting selectively to prostate can be achieved via the rat probasin promoter (pb) (or the prostate specific antigen promoter). Because tissue-specific prostate targeting exists using the probasin promotor, delivery of vectors systemically or by direct introduction into the prostate will result in death of transfected prostate cancer cells with some collateral damage also being observed in the remaining normal prostate epithelium. Because of the rather unique specificity of the probasin promoter, no additional collateral damage is expected to be observed elsewhere in the body. This is also expected to be true for the prostate-specific antigen.
Examples of targets include the I(A) subunit of RNA polymerase I and II. Other internal targeted ribozymes are tested for in vitro and in vivo activity by the methods described.
Synthesis The primary double ribozyme vector depicted in Figure 1 was constructed. The two flanking ribozymes (bases 1 to 54 and 66 to 120) are capable of self-cleavage. A
third ribozyme (Figure 2)(bases 64 to 105) targeted to pol I mRNA is cloned between the flanking ribozymes. This internal ribozyme has 19 bases within two regions (TTCAAAGA-catalytic core-ACGAGGATCAG) that are anti-sense to the pol I
message and interact by base pairing in regions with minimal secondary structures to effect cleavage.
The internal pol I ribozyme was prepared by synthesis of an oligonucleotide (5' GGA AGA TCT TTC AAA GAC TGA TGA CTC CGT GAG GAC GAA ACG AGG
ATC AGA TCT TCC 3')(only the ribozyme sense strand is shown in its reverse complement). The Bgl II site used in cloning is underlined. Following appropriate restriction digestion with Bgl II the double-stranded oligonucleotide was cloned into the Bgl II site within the parent vector (Figure 1).
Delivery The prostate specific promoter, when coupled to the triple ribozyme construct, will be delivered to the prostate systemically via liposomes. Various routes of introduction into the blood vascular system (some bypassing the lung and liver) are evaluated as described. Orthotopic routes can also be utilized. The liposome vehicle is expected to be efficient enough to deliver the molecule to prostate cancer cells, because of a high degree of vascularization). Thus, curing or at least reducing tumor burden by this gene therapy approach is reasonably expected.
i 1 The following liposome proparations were used in these studies: (a) lipofectamine reagent (GIBCO BRL, Gaithersburg,lvID) is a polycationic lipid composed of a positively charged lipid, DOSPA, and the neutral lipid, DOPE, in a 3:1 molar ration; (b) the cationic lipid, DDAB, used in combination with DOPE at 2:1 or 0.6:1.0 ratios (Brunette et al. Mol. Cell. Biol. 14:2411-2418, 1994); and (c) DIVIRIE in combination with DOPE in a 1:1 molar ratio (Felgner et al. Methods (Orlando) 5:67-75, 1995), obtained from VICAL Corp. (San Diego, CA). Liposome reagents were stored at 4 C prior to transfection.
Testing Once sequenced, these ribozymes are functionally tested: The test mechanism involves transcription of the triple ribozyme using one of the two possible bacterial promoters, in this case SP-6 or T-7 present in the pCRII vector (Invitrogen, San Diego, Ca), (in the presence of trace amounts of radioactivity) followed by evaluating the . autocatalytic cleavage of the ribozyme by electrophoresis. This was carried out with the pol I ribozyme and cleavage was observed, i.e., first a 113 bp fragment was produced that included the iirternal targeting ribozyme and the 3' ribozyme, followed by the appearance of a 74 bp fragment containing the internal pol I ribozyme.
The ribozyme was subsequently tested by transient transfection it into C3H10T
1/2 mouse fibroblast cells. This demonstrated that pol I RNA was degraded when triple ribozyme expression was induced. Thus, two phases of the activity of the molecule have been examined and demonstrated to occur. Autocatalytic cleavage of the cis ribozymes and functional degradation of pol I mRNA in trans occur as expected.
A subsequent step is to introduce the triple-ribozyme into a vector under the control of a tissue-specific promoter such as probasin or prostate specific antigen that will target expression in a tissue-specific manner. This was done by taking the Not I
fragment containing the entire 3', 5' and intenlal ribozymes (Fig. 2) and subcloning it into a vector containing the probasin promoter region (-426 to +28 (Greenburg et al., * trademark 1994)). This promoter has been demonstrated to target gene expression to the prostate.
Vectors are tested in vivo in transgenic mice expressing the triple ribozyme anti-pol I construct. Transgenic mice are generated by standard pronuclear injection as 5 described in Hogan (Manipulating the mouse embryo: a laboratory manual, Cold Spring Harbor, NY 1986). Prior to injection, constructs are separated from vector DNA
by restriction digestion (H'ind III and Sac II) of the plasmid, followed by sucrose gradient fractionation. Isolated constructs are dialyzed against 10mm tris ph 8.0, 0.1mm EDTA
before injection. In these mice, once probasin expression becomes apparent at the 3-5 10 week stage of post natal development destruction of prostate epithelium is expected to occur. The efficiency of generating transgenic mice is 10-15% with twenty-six mice delivered, i.e. 2-3 transgenic mice are predicted. Another way to verify the present ribozymes' functionality is to introduce the vector into tissue culture, e.g., human PC3 prostate cancer cells, and observe cell death in response to activation of the ribozyme.
15 C3H10T 1/2 mouse fibroblasts have been confirmed as sensitive to the pol I
triple ribozyme.
Further validation of this gene therapy approach is obtained through in vivo studies. Two such studies have been performed. In the first case, a control vector, 20 more easily monitored than the pol I ribozyme, which consists of the probasin promoter driving expression of the algal green fluorescent protein was used to ascertain the effectiveness of the in vivo liposomal delivery system. The procedure involves mice that are anesthetized and prepared by a surgical procedure to expose the descending aorta. A 30 gauge catheter is placed in the descending aorta followed by introduction of 300,ug vector/kilogram body weight (vector: liposome ratio of 10gg/40,u1). The results verify that expression of the green fluorescent protein occurs in dorsolateral prostate epithelium but not in the lung (a normal target of liposomes). Further studies determine if expression is observed in liver and other tissue including the kidney, adrenal gland and the brain. A second experiment has also been carried out in which the po1 I
ribozyme was introduced in vivo using the same method described above. In both cases where either the triple ribozyme or the green fluorescent protein was introduced, animals were euthanized at various time post operatively, autopsied, and tissues were examined for activity of the vector by immunohistochemistry. There was evidence of some apoptotic cell death in prostate epithelium at seven days following administration.
In vivo studies are conducted in transgenic mice bearing prostate tumors.
Tumors are induced by probasin directed expression of genes such as EcoRl (a restriction enzyme), cfos (a proto-oncogene), or a modified version of lamin (a nuclear matrix molecule). Administration of the ribozyme is as described above.
Target Choice Various molecules have been chosen for targeting. The first is RNA polymerase 1(A). This represents an excellent target, because it is an abundant RNA. If there is a leakiness (low levels of transcription) of the probasin promoter in other than prostate cells, they are predicted to survive the presence of limited levels of the Pol I ribozyme.
Other potential targets will be examined including phosphofructokinase (ribozyme targets nt 178, 121, or 162 depending on tissue involved), RNA pol II subunit 14.4 kd (ribozyme targets nt 83 or 884), mRNA pol II 140 kd subunit (ribozyme targets nt 204), and RNA pol 1123 kd subunit (ribozyme targets nt 143).
Another potential target of interest is the 70 kD subunit of replication protein A.
It is needed for formation of DNA replication centers/foci, so it should disrupt DNA
replication without danger of introducing errors. The sequence reference is Kim, et al., Mol. Cell. Biol. 12:3050-3059, 1992.
RI[BOZYME GENE THERAPY IN PARASITIC INFECTION
The methods described above are applicable to the present context, except where specified. For example, The administration mode will be different for parasitic infection than for prostate cancer and will depend upon tissue site.
For malaria (Plasmodiumfalciparum) the EMP-1 proteins, which are necessary for cytoadherence and present a problem because they cause rapid antigenic variation, are targeted. Specifically, highly conserved GTCs in exon II are targeted.
Pertinent EMBL accession numbers are L42246, L42244, L42245, L42247, L40600-L40609, L42636. See Smith, J. et al. Cel182:101-110, 1995, and Su, X. et al. Cell 82:89-100, 1995. A promoter active in red blood cells can be used and treatment also could be extracorporeal.
RIBOZYME GENE THERAPY IN BACTERIAL INFECTION
The methods described above are applicable to the present context, except where specified. For example, The administration mode will be different for bacterial infection than for prostate cancer, and will depend on the targeted tissue.
For Mycobacterium tuberculosis, a transcribed fragment which is essential for cell entry will be targeted. The EMBL accession number is X70901. See Arruda, S. et al. Science 261:1454-1457, 1993. The target will be near the N-terminus of the open reading frame coding for the 52 kD protein, from the 1535 bp fragment.
RIBOZYME GENE THERAPY IN VIRAL INFECTION
The methods described above are applicable to the present context, except where specified. For example, the administration mode will be different for viral infection than for prostate cancer.
Human papillomavirus type 16 E6 and E7 proteins are translated from a bicistronic mRNA. Antisense oligonucleotides to the translational start site of E6 inhibit synthesis of both E6 and E7. The target will be a GTT, cleaving at nt 108 (Tan, et al., J. Gen. Virol. 75:2663-2670, 1994). Original numbering is from Seedort, et al., Virology 145:181-185, 1985. IV and topical administration should be an effective combination.
Topical administration should be effective for dysplastic/precancerous lesions.
Hepatitis B virus is a partially single-stranded DNA virus, and it is now thought that integration of the viral genome is not the critical incident. Rather, the viral genome is made into an extended RNA intermediate, which is then reverse transcribed into DNA. A target with multiple advantage has been chosen. It will cut the viral RNA
pregenome in the first place, and its located in both the S (envelope) and polymerase/reverse transcriptase domains. The cut is at a GTC, after nt 438 in the HBV
subtype ayw. The EMBL accession number is X02496, and the original sequence reference is Galibert, et al., Nature 281, 646-650, 1979. Expression could be driven by the albuming promoter and IV administration should be highly effective.
While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.
Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Pertinent EMBL accession numbers are L42246, L42244, L42245, L42247, L40600-L40609, L42636. See Smith, J. et al. Cel182:101-110, 1995, and Su, X. et al. Cell 82:89-100, 1995. A promoter active in red blood cells can be used and treatment also could be extracorporeal.
RIBOZYME GENE THERAPY IN BACTERIAL INFECTION
The methods described above are applicable to the present context, except where specified. For example, The administration mode will be different for bacterial infection than for prostate cancer, and will depend on the targeted tissue.
For Mycobacterium tuberculosis, a transcribed fragment which is essential for cell entry will be targeted. The EMBL accession number is X70901. See Arruda, S. et al. Science 261:1454-1457, 1993. The target will be near the N-terminus of the open reading frame coding for the 52 kD protein, from the 1535 bp fragment.
RIBOZYME GENE THERAPY IN VIRAL INFECTION
The methods described above are applicable to the present context, except where specified. For example, the administration mode will be different for viral infection than for prostate cancer.
Human papillomavirus type 16 E6 and E7 proteins are translated from a bicistronic mRNA. Antisense oligonucleotides to the translational start site of E6 inhibit synthesis of both E6 and E7. The target will be a GTT, cleaving at nt 108 (Tan, et al., J. Gen. Virol. 75:2663-2670, 1994). Original numbering is from Seedort, et al., Virology 145:181-185, 1985. IV and topical administration should be an effective combination.
Topical administration should be effective for dysplastic/precancerous lesions.
Hepatitis B virus is a partially single-stranded DNA virus, and it is now thought that integration of the viral genome is not the critical incident. Rather, the viral genome is made into an extended RNA intermediate, which is then reverse transcribed into DNA. A target with multiple advantage has been chosen. It will cut the viral RNA
pregenome in the first place, and its located in both the S (envelope) and polymerase/reverse transcriptase domains. The cut is at a GTC, after nt 438 in the HBV
subtype ayw. The EMBL accession number is X02496, and the original sequence reference is Galibert, et al., Nature 281, 646-650, 1979. Expression could be driven by the albuming promoter and IV administration should be highly effective.
While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.
Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: MEDICAL UNIVERSITY OF SOUTH CAROLINA;
171 Ashley Avenue Charleston, South Carolina 29464; and PENN STATE RESEARCH FOUNDATION
(ii) TITLE OF INVENTION:
TISSUE-SPECIFIC AND TARGET RNA-SPECIFIC RIBOZYMES
(iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: GOWLING, STRATHY & HENDERSON
(B) STREET: Suite 2600, 160 Elgin Street (C) CITY: Ottawa (D) PROVINCE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE: K1P 1C3 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: MS-DOS 6.20 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
INTERNATIONAL APPLICATION NUMBER: PCT/US96/18088 CANADIAN APPLICATION NUMBER: Not Yet assigned FILING DATE: NOVEMBER 8, 1996 (viii) PATENT AGENT INFORMATION:
(A) NAME: Eli J. McKhool (B) REFERENCE NUMBER: 08-879558CA
5 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 184 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 10 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(1) GENERAL INFORMATION:
(i) APPLICANT: MEDICAL UNIVERSITY OF SOUTH CAROLINA;
171 Ashley Avenue Charleston, South Carolina 29464; and PENN STATE RESEARCH FOUNDATION
(ii) TITLE OF INVENTION:
TISSUE-SPECIFIC AND TARGET RNA-SPECIFIC RIBOZYMES
(iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: GOWLING, STRATHY & HENDERSON
(B) STREET: Suite 2600, 160 Elgin Street (C) CITY: Ottawa (D) PROVINCE: Ontario (E) COUNTRY: Canada (F) POSTAL CODE: K1P 1C3 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: MS-DOS 6.20 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
INTERNATIONAL APPLICATION NUMBER: PCT/US96/18088 CANADIAN APPLICATION NUMBER: Not Yet assigned FILING DATE: NOVEMBER 8, 1996 (viii) PATENT AGENT INFORMATION:
(A) NAME: Eli J. McKhool (B) REFERENCE NUMBER: 08-879558CA
5 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 184 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double 10 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Claims (26)
1. A nucleic acid comprising a target-specific promoter binding site upstream from a sequence encoding a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
2. The nucleic acid of claim 1, wherein the target-specific promoter binding site is the binding site for the probasin promoter.
3 The nucleic acid of claim 1, wherein the nucleic acid encoding the 5' autocatalytically cleaving ribozyme has the sequence of nucleotides 9-62 set forth in the Sequence Listing as SEQ ID NO:1.
4. The nucleic acid of claim 1, wherein the nucleic acid encoding the 3' autocatalytically cleaving ribozyme has the sequence of nucleotides 119-172 set forth in the Sequence Listing as SEQ ID NO:1.
5. The nucleic acid of claim 1, wherein the nucleic acid encoding the catalytic ribozyme comprising, a target RNA-specific binding site that binds to an RNA
sequence unique to ribosomal RNA (polymerase I(A)).
sequence unique to ribosomal RNA (polymerase I(A)).
6. The nucleic acid of claim 5, wherein the nucleic acid has the sequence of nucleotides 72-113 set forth in the Sequence Listing as SEQ ID NO: 1.
7. The nucleic acid of claim 1, consisting essentially of the nucleotides in the sequence set forth in the Sequence Listing as SEQ ID NO: 1.
8 The nucleic acid of claim 1, having the sequence set forth in the Sequence Listing as SEQ ID NO:1.
9. The nucleic acid of claim 1 in a vector.
10. The nucleic acid of claim 2 in a vector.
11. The nucleic acid of claim 3 in a vector.
12. The nucleic acid of claim 4 in a vector.
13. The nucleic acid of claim 5 in a vector.
14. The nucleic acid of claim 6 in a vector.
15. The nucleic acid of claim 7 in a vector.
16. The nucleic acid of claim 8 in a vector.
17. A transgenic non-human animal cell, containing the nucleic acid of claim 1, wherein the cell expresses a ribozyme comprising a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
18. A transgenic non-human animal cell, containing. the nucleic acid of claim 7, wherein the cell expresses a ribozyme comprising a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
19. A transgenic non-human animal cell, containing the nucleic acid of claim 8, wherein the cell expresses a ribozyme comprising a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme sequence.
20. The transgenic non-human animal cell of claim 17, wherein the cell does not express a phenotype associated with the target RNA.
21. A use of the nucleic acid of claim 5, for treating a subject having a proliferative disease of a specific tissue by inhibiting cell proliferation of the tissue, wherein the target-specific promoter binding sequence is specific for the diseased tissue, whereby the ribozyme encoded by the nucleic acid is expressed, ribosomal RNA production in the tissue is inhibited, cell proliferation is inhibited, and the proliferative disease is treated.
22. A use of the nucleic acid of claim 7, for treating a subject having prostate cancer, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
23. A use of the nucleic acid of claim 1, for treating an infection in a subject, wherein the encoded target RNA-specific binding site is specific for an RNA
unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed.
unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed.
24. A use of the nucleic acid of claim 5, for the production of a medicament for treating a subject having a proliferative disease of a specific tissue by inhibiting cell proliferation of the tissue, wherein the target-specific promoter binding sequence is specific for the diseased tissue, whereby the ribozyme encoded by the nucleic acid is expressed, ribosomal RNA
production in the tissue is inhibited, cell proliferation is inhibited, and the proliferative disease is treated.
production in the tissue is inhibited, cell proliferation is inhibited, and the proliferative disease is treated.
25. A use of the nucleic acid of claim 7, for the production of a medicament for treating a subject having prostate cancer, whereby the ribozyme encoded by the nucleic acid is expressed in the prostate and the prostate cancer is treated.
26. A use of the nucleic acid of claim 1, for the production of a medicament for treating an infection in a subject, wherein the encoded target RNA-specific binding site is specific for an RNA unique to the infectious agent, whereby the ribozyme encoded by the nucleic acid is expressed and the infectious agent is killed.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/554,369 US5824519A (en) | 1995-11-08 | 1995-11-08 | Tissue-specific and target RNA-specific ribozymes |
US08/554,369 | 1995-11-08 | ||
PCT/US1996/018088 WO1997017433A1 (en) | 1995-11-08 | 1996-11-08 | Tissue-specific and target rna-specific ribozymes |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2236998A1 CA2236998A1 (en) | 1997-05-15 |
CA2236998C true CA2236998C (en) | 2007-05-29 |
Family
ID=38149860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002236998A Expired - Fee Related CA2236998C (en) | 1995-11-08 | 1996-11-08 | Tissue-specific and target rna-specific ribozymes |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2236998C (en) |
-
1996
- 1996-11-08 CA CA002236998A patent/CA2236998C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2236998A1 (en) | 1997-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0866852B1 (en) | Tissue-specific and target rna-specific ribozymes | |
US10167470B2 (en) | Antisense oligonucleotides for the treatment of leber congenital amaurosis | |
AU702373B2 (en) | Stabilized external guide sequences | |
JP4062365B2 (en) | Short external guide arrangement | |
US5814500A (en) | Delivery construct for antisense nucleic acids and methods of use | |
US8389487B2 (en) | siRNA-mediated gene silencing of synuclein | |
Sullivan | Development of ribozymes for gene therapy | |
ES2739850T3 (en) | Nucleic acids and procedures for the treatment of Pompe disease | |
MXPA06012605A (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells. | |
WO1995031552A2 (en) | Human papilloma virus inhibition by a hairpin ribozyme | |
US8008471B2 (en) | Nucleic acids for inhibiting hairless protein expression and methods of use thereof | |
WO1996018733A2 (en) | Ribozyme-mediated inactivation of leukemia-associated rna | |
CA2236998C (en) | Tissue-specific and target rna-specific ribozymes | |
WO2000009672A9 (en) | Dnazymes and methods for treating restenosis | |
Phylactou et al. | Utilization of properties of natural catalytic RNA to design and synthesize functional ribozymes | |
CA2578402A1 (en) | Human papilloma virus inhibition by a hairpin ribozyme | |
EP0759992A1 (en) | Human papilloma virus inhibition by a hairpin ribozyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |